PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Panagene

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Panagene Reaches Settlement of Patent Infringement Cases with Biosynthesis - Panagene and Biosynthesis, Inc. (Lewisville, Texas) have agreed to settle Panagene’s allegations of patent infringement that were pending in the United States District Court for the Eastern District of Texas - Panagene.com
Panagene Reaches Settlement of Patent Infringement Cases with Biosynthesis

 

NewswireToday - /newswire/ - Daejeon, Chungchungnamdo, Korea (South), 2012/12/20 - Panagene and Biosynthesis, Inc. (Lewisville, Texas) have agreed to settle Panagene’s allegations of patent infringement that were pending in the United States District Court for the Eastern District of Texas - Panagene.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Panagene, Inc. announced today that Panagene and Biosynthesis, Inc. (Lewisville, Texas) have agreed to settle Panagene’s allegations of patent infringement that were pending in the United States District Court for the Eastern District of Texas. The terms of the settlement include Biosynthesis’ undisclosed payments of past damages and stopping immediately all PNA products sales and PNA-related services. Panagene alleged that Biosynthesis’ PNA products and PNA-related services infringe two patents exclusively licensed by Panagene: United States Patent Nos. 6,395, 474 and 7,378, 485. These patents cover multiple aspects of PNA (Peptide nucleic acids, artificial DNA) material and technology, including PNA oligomers, PNA monomers, and PNA uses in diagnostics.

“Intellectual properties are keys of advancing technology and Panagene is investing significant resources to develop and license in new technologies to support the needs of the advanced PNA diagnostic for personalized medicine and therapeutic market. We have, and will continue to enforce our patent rights,” said Dr. Sungkee Kim, President and CEO of Panagene, Inc. “Panagene is pleased to have achieved a favorable resolution of the patent infringement action against Biosynthesis.”

About Panagene

Panagene, Inc. (panagene.com), a listed company headquartered in Daejeon, Korea, is exclusively licensed PNA supplier worldwide. Panagene developed and patented efficient PNA production processes for PNA oligomers in high purity and large quantities. Panagene have also developed PNA-based diagnostic technology such as PNAClamp™ and PANArray™ (PNA microarray chip) and delivers highly sensitive and specific diagnostic products for detections of gene mutations and genotypes of pathogens.

Panagene has distributors in the U.S., Austria, Belgium, Bulgaria, China, Czech Republic, India, Iran, Israel, Japan, Spain, Taiwan, and UK.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Panagene

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Panagene Reaches Settlement of Patent Infringement Cases with Biosynthesis

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Tae Kim - Panagene.com 
805-480-4897 info[.]panagene.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Panagene securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Panagene / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)